Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Phase IIa Study to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Patients With Recurrent or Metastatic HER-2 Negative Breast Cancer, Suitable for Treatment With a Taxane

NCT03890744 is registered in ClinicalTrials.gov with Modra Pharmaceuticals as lead sponsor.

NCT NCT03890744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03890744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Phase IIa Study to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Patients With Recurrent or Metastatic HER-2 Negative Breast Cancer, Suitable for Treatment With a Taxane
Lead sponsor
Modra Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
January 30, 2019
Completion date
November 9, 2020
Enrollment
12 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, recurrent breast cancer